Arca
Skip to content
Tools
Tools

Non-small cell lung cancer

Drug research and approvals for non-small cell lung cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,311 studies of non-small cell lung cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 314 drug trials for it since 2013, FDA has 39 approved and 18 open orphan designations naming it, and the EU has 14 authorised medicines for it.

  • Recruiting worldwide: 1,311
  • Trials authorized in Canada: 314
  • FDA orphan approvals: 39
  • EU medicines: 14

Recruiting now

Newest posted first, of 1,311 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24 of 37

Phase 3 12 of 133

Phase 2 12 of 282

  • VorinostatHistone deacetylase 1 inhibitor
  • TrametinibDual specificity mitogen-activated protein kinase kinase 2 inhibitor
  • IrinotecanDNA topoisomerase I inhibitor
  • BinimetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
  • EverolimusFK506-binding protein 1A inhibitor
  • PazopanibMacrophage colony stimulating factor receptor inhibitor
  • Bortezomib26S proteasome inhibitor
  • DasatinibTyrosine-protein kinase ABL inhibitor
  • EnvafolimabProgrammed cell death 1 ligand 1 binding agent
  • ItraconazoleCytochrome P450 51 inhibitor
  • AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
  • NimotuzumabEpidermal growth factor receptor erbB1 inhibitor

Phase 1 or earlier 12 of 193

How its trials ended

5,613 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 1,514 whose ending is known, 27% met their primary endpoint, 10% missed it and 63% stopped early.

  • Ongoing1,61429%
  • Completed, result not reported1,61129%
  • Status unknown87416%
  • Stopped: other or unclear4278%
  • Met its primary endpoint4057%
  • Stopped: enrollment or feasibility2474%
  • Missed its primary endpoint1543%
  • Stopped: sponsor or business decision1533%
  • Stopped: lack of efficacy761%
  • Stopped: funding311%
  • Stopped: safety21<1%

Trials authorized in Canada

The 10 newest of 314; search them all in Canada trials
Oct 27, 2026Luna-2: a phase II randomized trial of LND101 for fecal microbiota transplantation in combination with immune checkpoint blockade and chemotherapy in…LND101Canadian Cancer Trials Group, Cancer Research Institute, Queen's UniversityPending
Oct 22, 2026Rosetta LUNG-220: a phase 2, open-label, multicenter, multi-arm platform study evaluating pumitamig and other novel neoadjuvant regimens in participants with…Pumitamig (BMS-986545; BNT327)Bristol-Myers SquibbPending
Oct 15, 2026A phase 3 open label randomized study of telisotuzumab adizutecan compared to standard of care in subjects with previously treated, EGFR wildtype, locally…Telisotuzumab adizutecan (ABBV-400)AbbViePending
Oct 9, 2026A phase 3, open-label study of ivonescimab vs durvalumab as consolidation therapy in patients with locally advanced, unresectable NSCLC (stage iii) who have…IvonescimabSummit TherapeuticsPending
Sep 11, 2026A phase III, randomized, open-label study of izalontamab brengitecan (BMS-986507) in combination with osimertinib versus osimertinib monotherapy or osimertinib…Izalontamab brengitecan (BMS-986507) / Tagrisso (osimertinib)Bristol-Myers SquibbOngoing
Jun 30, 2026A global, multicentre, phase II platform study of datopotamab deruxtecan (dato-dxd)-based combinations in adult participants with TROP2 nmr-positive non-small…Datopotamab deruxtecan / Durvalumab / CarboplatinAstraZeneca PharmaceuticalsPending
Jun 25, 2026An interventional, phase 1 b, double-blind, randomized, sponsor-open, 2-arm study to investigate the effect of ponsegromab on skeletal muscle mass and physical…Ponsegromab (PF-06946860)PfizerPending
Jun 2, 2026A phase III, randomized, open-label study evaluating the efficacy and safety of divarasib compared with investigator’s choice of immunotherapy or observation…Divarasib (GDC-6036; RO7435846) / Pembrolizumab / NivolumabRocheOngoing
May 22, 2026A multicenter, first-in-human, dose escalation and optimization phase I/IIa study to investigate safety, tolerability, pharmacokinetics, and efficacy of the…TUB-040Tubulis GmbHPending
May 12, 2026An interventional, open-label, phase 2 study to investigate the safety and efficacy of PF-08634404 monotherapy or in combination in adult participants with…PF-08634404 (SSGJ-707) / Carboplatin / Paclitaxel / PemetrexedPfizerPending

FDA orphan designations

Approved first, then open designations, newest first; 15 of 57
Sep 9, 2026HyrnuoTreatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2…Bayer HealthCare Pharmaceuticals Inc.Approved
Jul 22, 2026JideytroTreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1…Nuvalent, Inc.Approved
Nov 19, 2025HyrnuoTreatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2…Bayer HealthCare Pharmaceuticals Inc.Approved
Jun 11, 2025IbtroziTreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)Nuvation Bio Inc.Approved
Sep 25, 2024TagrissoTreatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not…AstraZeneca Pharmaceuticals LPApproved
Apr 18, 2024AlecensaAdjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer…Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)Approved
Feb 16, 2024TagrissoIn combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or…AstraZeneca Pharmaceuticals LPApproved
Nov 15, 2023AugtyroTreatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)Bristol Myers Squibb CompanyApproved
Oct 11, 2023BraftoviIn combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E…Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.)Approved
Sep 7, 2023XalkoriTreatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or…Pfizer, Inc.Approved
Dec 12, 2022KrazatiTreatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an…Bristol-Myers Squibb CompanyApproved
Sep 21, 2022RetevmoTreatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection…Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and CompanyApproved
Sep 15, 2021ExkivityTreatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor…Takeda Development Center Americas, Inc.Approved
May 28, 2021LumakrasTreatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an…Amgen Inc.Approved
Mar 3, 2021LorbrenaTreatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive…Pfizer, Inc.Approved

Medicines authorised in the EU

Newest first
Jan 13, 2025AugtyroRepotrectinibBristol-Myers Squibb Pharma EEIGEMA ↗
Jan 5, 2024KrazatiAdagrasibBristol-Myers Squibb Pharma EEIGEMA ↗
Sep 15, 2023TevimbraTislelizumabBeone Medicines Ireland LimitedEMA ↗
Feb 16, 2022TepmetkoTepotinibMerck Europe B.V.EMA ↗
Jan 6, 2022LumykrasSotorasibAmgen Europe B.V.EMA ↗
Sep 21, 2018ImfinziDurvalumabAstraZeneca ABEMA ↗
Sep 20, 2018MektoviBinimetinibPierre Fabre MedicamentEMA ↗
Feb 1, 2016TagrissoOsimertinibAstraZeneca ABEMA ↗
Jan 18, 2016Pemetrexed AccordPemetrexed · genericAccord Healthcare S.L.U.EMA ↗
Jan 18, 2016Armisarte (previously Pemetrexed Actavis)PemetrexedActavis Group PTC ehfEMA ↗
Nov 19, 2015Pemetrexed Pfizer (previously Pemetrexed Hospira)Pemetrexed · genericPfizer Europe MA EEIGEMA ↗
Nov 21, 2014VargatefNintedanibBoehringer Ingelheim International GmbHEMA ↗
Sep 25, 2013GiotrifAfatinibBoehringer Ingelheim International GmbHEMA ↗
Sep 19, 2005TarcevaErlotinibCheplapharm Registration GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.